Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · November 16, 2023

Cardiovascular and Venous Thromboembolic Risk Associated With JAK Inhibitor Use in Patients With Immune-Mediated Inflammatory Skin Diseases

JAMA Dermatology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Dermatology
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis
JAMA Dermatol 2023 Nov 01;[EPub Ahead of Print], JP Ingrassia, MH Maqsood, JM Gelfand, BN Weber, S Bangalore, KI Lo Sicco, MS Garshick

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading